Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
出版年份 2018 全文链接
标题
Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
作者
关键词
Pancreatic neuroendocrine tumor, Tumor heterogeneity, [<sup>68</sup>Ga], [<sup>177</sup>Lu]-DOTATATE/-DOTATOC, PET/CT, SSTR
出版物
MOLECULAR IMAGING AND BIOLOGY
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2018-07-17
DOI
10.1007/s11307-018-1252-5
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues
- (2017) Rodney J. Hicks et al. NEUROENDOCRINOLOGY
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors
- (2017) Nancy Sharma et al. PANCREAS
- A phase II study of axitinib in advanced neuroendocrine tumors
- (2016) J R Strosberg et al. ENDOCRINE-RELATED CANCER
- Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE
- (2016) Maddalena Sansovini et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Intratumoral heterogeneity of 18F-FDG uptake predicts survival in patients with pancreatic ductal adenocarcinoma
- (2016) Seung Hyup Hyun et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- The asphericity of the metabolic tumour volume in NSCLC: correlation with histopathology and molecular markers
- (2016) Ivayla Apostolova et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate
- (2016) Hendrik Bergsma et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Texture analysis of 18F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy
- (2016) Masatoyo Nakajo et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Semiquantitative Parameters in PSMA-Targeted PET Imaging with 18 F-DCFPyL: Variability in Normal-Organ Uptake
- (2016) Xin Li et al. JOURNAL OF NUCLEAR MEDICINE
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
- (2016) James C Yao et al. LANCET
- Predictive Value of Asphericity in Pretherapeutic [111In]DTPA-Octreotide SPECT/CT for Response to Peptide Receptor Radionuclide Therapy with [177Lu]DOTATATE
- (2016) Christoph Wetz et al. MOLECULAR IMAGING AND BIOLOGY
- Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity
- (2016) Rudolf A. Werner et al. Oncotarget
- A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management
- (2016) Kjell Oberg et al. Endocrine Connections
- Revisiting the Robustness of PET-Based Textural Features in the Context of Multi-Centric Trials
- (2016) Clément Bailly et al. PLoS One
- Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development
- (2015) Rocio Garcia-Carbonero et al. CANCER AND METASTASIS REVIEWS
- Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy
- (2015) Thomas Pyka et al. Radiation Oncology
- Non–Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of18F-FDG Uptake at PET—Association with Treatment Response and Prognosis
- (2015) Gary J. R. Cook et al. RADIOLOGY
- False Discovery Rates in PET and CT Studies with Texture Features: A Systematic Review
- (2015) Anastasia Chalkidou et al. PLoS One
- Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours
- (2014) Samer Ezziddin et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 18F-FDG PET Uptake Characterization Through Texture Analysis: Investigating the Complementary Nature of Heterogeneity and Functional Tumor Volume in a Multi-Cancer Site Patient Cohort
- (2014) M. Hatt et al. JOURNAL OF NUCLEAR MEDICINE
- Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
- (2014) S. Ezziddin et al. JOURNAL OF NUCLEAR MEDICINE
- Textural Parameters of Tumor Heterogeneity in 18F-FDG PET/CT for Therapy Response Assessment and Prognosis in Patients with Locally Advanced Rectal Cancer
- (2014) R. A. Bundschuh et al. JOURNAL OF NUCLEAR MEDICINE
- SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors
- (2014) C. Kratochwil et al. MOLECULAR IMAGING AND BIOLOGY
- Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
- (2014) Hugo J. W. L. Aerts et al. Nature Communications
- The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
- (2013) John J. Zaknun et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Pancreatic Enucleation: Improved Outcomes Compared to Resection
- (2012) C. E. Cauley et al. JOURNAL OF GASTROINTESTINAL SURGERY
- The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors
- (2011) Ben Lawrence et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- Baseline 18F-FDG PET image-derived parameters for therapy response prediction in oesophageal cancer
- (2011) Mathieu Hatt et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Intratumor Heterogeneity Characterized by Textural Features on Baseline 18F-FDG PET Images Predicts Response to Concomitant Radiochemotherapy in Esophageal Cancer
- (2011) F. Tixier et al. JOURNAL OF NUCLEAR MEDICINE
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy
- (2010) Samer Ezziddin et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Distant metastasis occurs late during the genetic evolution of pancreatic cancer
- (2010) Shinichi Yachida et al. NATURE
- Evaluation of spatial resolution of a PET scanner through the simulation and experimental measurement of the recovery coefficient
- (2009) E. Prieto et al. COMPUTERS IN BIOLOGY AND MEDICINE
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
- (2009) Anja Rinke et al. JOURNAL OF CLINICAL ONCOLOGY
- 68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor-Mediated Radionuclide Therapy
- (2009) M. Gabriel et al. JOURNAL OF NUCLEAR MEDICINE
- Methods and Limitations of Assessing New Noninvasive Tests
- (2008) Rory Hachamovitch et al. CIRCULATION
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival
- (2008) Dik J. Kwekkeboom et al. JOURNAL OF CLINICAL ONCOLOGY
- Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors
- (2008) Anne Couvelard et al. MODERN PATHOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started